Lichen planopilaris-like eruption in chronic myeloid leukemia patient during treatment with nilotinib as second-line therapy. (June 2022)

• Record Type: Journal Article
• Authors: Gardellini, Angelo; Guidotti, Francesca; Zancanella, Michelle; Maino, Elena; Steffanoni, Sara; Turrini, Mauro
• Is Part Of: Journal of oncology pharmacy practice. Volume 28:Number 4(2022)
• Page Start: 969
• Page End: 971
• Publication Date: 2022-06
• Subjects: Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/10781552211073957
• Languages: English
• ISSNs: 1078-1552

Abstract

Introduction: Chronic myeloid leukemia (CML) is a malignant clonal disorder of hematopoietic stem cells characterized by a translocation of genetic material between chromosomes 9 and 22 resulting in the BCR-ABL fusion oncogene expression. Nilotinib is a potent second-generation tyrosine kinase inhibitor available as first line treatment. Among side effects QTc interval prolongation, pancreatitis, metabolic disorders and skin reactions are the most commonly seen. Case Report: Here we describe a rare case of lichen planopilaris eruption that developed during therapy with nilotinib. Management & Outcome: Nilotinib dosage was reduced together with introduction of hydroxychloroquine with progressive improvement of alopecia. Discussion: Collaboration with dermatologist and nilotinib dose reduction allowed to continue the drug maintaining major molecular response and patient's quality of life.